157 related articles for article (PubMed ID: 2046904)
1. Reduction in sella turcica volume. An effect of long-term treatment with the somatostatin analogue, SMS 201-995, in acromegalic patients.
Lund E; Jørgensen J; Christensen SE; Weeke J; Orskov H; Harris AG
Neuroradiology; 1991; 33(2):162-4. PubMed ID: 2046904
[TBL] [Abstract][Full Text] [Related]
2. Effect of long-term treatment with somatostatin analogue (SMS 201-995) on pituitary tumor shrinkage in acromegaly--report of two cases.
Mukada K; Uozumi T; Takechi A; Arita K; Yano T; Hirohata T; Onda J; Ohta M
Neurol Med Chir (Tokyo); 1992 Apr; 32(4):215-9. PubMed ID: 1378566
[TBL] [Abstract][Full Text] [Related]
3. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.
Shi YF; Harris AG; Zhu XF; Deng JY
Clin Endocrinol (Oxf); 1990 Jun; 32(6):695-705. PubMed ID: 2200620
[TBL] [Abstract][Full Text] [Related]
4. Medical management of acromegaly: effects of SMS 201-995 in 30 patients.
Pagani G; Montini M; Gianola D; Pagani MD; Tengattini F; Dominoni P; Ghilardi G; Cortesi L; Pedroncelli A; Tonnarelli GP
Endocrinol Exp; 1990 Mar; 24(1-2):175-85. PubMed ID: 2361459
[TBL] [Abstract][Full Text] [Related]
5. [The sella turcica in acromegaly. Radiological study].
Vezina JL; Maltais R
Neurochirurgie; 1973 May; 19(2):Suppl 2:35-56. PubMed ID: 4356510
[No Abstract] [Full Text] [Related]
6. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
Lamberts SW; Uitterlinden P; del Pozo E
J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
[TBL] [Abstract][Full Text] [Related]
7. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
8. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
Barakat S; Melmed S
Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
[TBL] [Abstract][Full Text] [Related]
9. Co-existing pituitary adenoma and intrasellar arachnoid invagination.
Sutton TJ; Vezina JL
Am J Roentgenol Radium Ther Nucl Med; 1974 Nov; 122(3):508-10. PubMed ID: 4432974
[No Abstract] [Full Text] [Related]
10. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.
Legovini P; De Menis E; Billeci D; Conti B; Zoli P; Conte N
J Endocrinol Invest; 1997; 20(7):424-8. PubMed ID: 9309542
[TBL] [Abstract][Full Text] [Related]
11. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group.
Sassolas G; Harris AG; James-Deidier A
J Clin Endocrinol Metab; 1990 Aug; 71(2):391-7. PubMed ID: 2199479
[TBL] [Abstract][Full Text] [Related]
12. Reduced intercarotid artery distance in acromegaly: pathophysiologic considerations and implications for transsphenoidal surgery.
Ebner FH; Kuerschner V; Dietz K; Bueltmann E; Naegele T; Honegger J
Surg Neurol; 2009 Nov; 72(5):456-60; discussion 460. PubMed ID: 19963090
[TBL] [Abstract][Full Text] [Related]
13. An enlarged sella turcica on cephalometric radiograph.
Chang HP; Tseng YC; Chou TM
Dentomaxillofac Radiol; 2005 Sep; 34(5):308-12. PubMed ID: 16120882
[TBL] [Abstract][Full Text] [Related]
14. Paradoxic elevation in serum GH by hypothalamic releasing hormones predicts GH response to acute SMS 201-995 administration.
Candrina R
Recenti Prog Med; 1991 Jan; 82(1):13-6. PubMed ID: 1902962
[TBL] [Abstract][Full Text] [Related]
15. Effective treatment of recurrent acromegaly with a long-active somatostatin analogue (sandostatin).
Miranda R; Zárate A; Ruíz Velasco G
Arch Invest Med (Mex); 1988; 19(4):445-8. PubMed ID: 3245759
[No Abstract] [Full Text] [Related]
16. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone rebound after cessation of sms 201-995 treatment in acromegaly.
Charest L; Comtois R; Beauregard H; Serri O
Can J Neurol Sci; 1989 Nov; 16(4):442-5. PubMed ID: 2804808
[TBL] [Abstract][Full Text] [Related]
18. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
[TBL] [Abstract][Full Text] [Related]
19. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.
Davies PH; Stewart SE; Lancranjan L; Sheppard MC; Stewart PM
Clin Endocrinol (Oxf); 1998 Mar; 48(3):311-6. PubMed ID: 9578821
[TBL] [Abstract][Full Text] [Related]
20. [Empty sella turcica syndrome. Comments with report of a case].
Diaz Fernández AJ; Shum C; Merchante Iglesias A; Vila Canella T; Colomé Pavón JA; de Pablo Martínez MI
Rev Clin Esp; 1975 Oct; 139(2):179-82. PubMed ID: 172986
[No Abstract] [Full Text] [Related]
[Next] [New Search]
